Stephane Alexandre Regnier (Stephane A Regnier, Stephane Regnier)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 7

Top Topics

Randomized Controlled Trial

Neuropathic Pain

Top Venues

PharmacoEconomics

Journal of medical economics

Expert review of pharmacoeconomics & outcomes research

This page only lists publications with an associated author ORCID identifier.

Publications

Tobias Sydendal Grand, Shijie Ren, James A Hall, Daniel Oudin Åstrøm, Stephane Alexandre Regnier, Praveen Thokala
Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review. PharmacoEconomics 42 (6) (2024)
Tobias Sydendal Grand, Shijie Ren, James A Hall, Daniel Oudin Åstrøm, Stephane Alexandre Regnier, Praveen Thokala
Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review. PharmacoEconomics 42 (6) (2024)
Tobias Sydendal Grand, Shijie Ren, James A Hall, Daniel Oudin Åstrøm, Stephane Alexandre Regnier, Praveen Thokala
Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review. PharmacoEconomics (2024)
Tobias Sydendal Grand, Shijie Ren, James A Hall, Daniel Oudin Åstrøm, Stephane Alexandre Regnier, Praveen Thokala
Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review. PharmacoEconomics 42 (6) (2024)
Tobias Sydendal Grand, Shijie Ren, James A Hall, Daniel Oudin Åstrøm, Stephane Alexandre Regnier, Praveen Thokala
Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review. PharmacoEconomics 42 (6) (2024)
Stephane Alexandre Regnier, Xin Ying Lee
Meta-regression to explain the placebo effects in clinical trials of anti-CGRP monoclonal antibodies for migraine prevention. Journal of medical economics (2023)
Linus Jönsson, Stephane Alexandre Regnier, Steven Kymes, Susanne F Awad, Brian Talon, Xin Ying Lee, Peter J Goadsby
Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial. Expert review of pharmacoeconomics & outcomes research (2023)